Recruiting
PANCEP-1
2023-506979-10-00· Phase 1/2· Vaestra Goetalandsregionen· Source
Recruiting
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)
2023-506998-35-00· Phase 3· Vaestra Goetalandsregionen· Source
Recruiting
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482· Phase 3· Uppsala University· Source
Recruiting
One-Month DAPT in CABG Patients
NCT05997693· Phase 3· Weill Medical College of Cornell University· Source
Recruiting
A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients with Uveal Melanoma Liver Metastases – the SCANDIUM III trial.
2023-508156-20-00· Phase 3· Vaestra Goetalandsregionen· Source
Recruiting
Cancer Related Major Depression Treated With a Single Dose of Psilocybin
NCT06319378· Phase 2· Section for Affective Disorders; Northern Stockholm Psychiatry· Source
Recruiting
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
NCT05852704· Phase 3· Region Örebro County· Source
Active, not recruiting
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· Phase 3· AstraZeneca· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· Phase 3· AstraZeneca· Source
Active, not recruiting
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· Phase 3· Boehringer Ingelheim· Source
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486· Phase 3· Sanofi· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835· Phase 3· AstraZeneca· Source
Recruiting
Short or long NAT for BR/LAPC (ADVANTAGE Trial)
2022-502117-29-00· Phase 3· Vastra Gotalandsregionen· Source
Active, not recruiting
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326· Phase 2· Genentech, Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation
NCT05939076· Phase 3· Region Örebro County· Source
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941· Phase 4· Novartis Pharmaceuticals· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182· Phase 3· AbbVie· Source
Active, not recruiting
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma
2022-501463-40-01· Phase 3· Servier Affaires Medicales· Source
Active, not recruiting
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· Phase 3· Bayer· Source
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source
Active, not recruiting
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· Phase 3· Genmab· Source
Recruiting
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
NCT05669950· Phase 1/2· H. Lundbeck A/S· Source
Active, not recruiting
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Active, not recruiting
Ixekizumab Diabetes Intervention Trial (I-DIT)
NCT04589325· Phase 2· Göteborg University· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· Phase 3· Hoffmann-La Roche· Source
Recruiting
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00· Phase 3· GPOH gGmbH· Source
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· Phase 3· AbbVie· Source
Active, not recruiting
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with extensive stage small-cell lung cancer?
NCT05223647· Phase 3· Norwegian University Of Science And Technolology· Source
Active, not recruiting
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717· Phase 3· Amgen· Source
Active, not recruiting
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
PiSCATIN - Simvastatin for the treatment of primary sclerosing cholangitis (PSC) - a randomized double-blind, placebo-controlled multicenter study
2024-511053-22-00· Phase 2· Karolinska University Hospital· Source
Active, not recruiting
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
NCT04335669· Phase 3· Lund University Hospital· Source
Recruiting
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
NCT03685890· Phase 1/2· Vastra Gotaland Region· Source
Recruiting
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
NCT03583710· Phase 3· M.D. Anderson Cancer Center· Source
Active, not recruiting
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318· Phase 3· AbbVie· Source
Active, not recruiting
Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome
NCT03560310· Phase 4· Vastra Gotaland Region· Source